Scientists argue that studies of infection-triggered chronic conditions are flawed due to unproven diagnoses. Rutgers University researchers highlight methodological shortcomings in Lyme disease research and suggest rigorous study design is needed.
Thousands of Americans develop chronic, persistent symptoms such as fatigue, cognitive difficulties ("brain fog"), and other debilitating issues each year following acute infections from diseases like Lyme disease, COVID-19, and others. Efforts to identify causes and produce treatments have failed, according to a recent article in Brain by researchers from Rutgers University and other institutions.
Steven Schutzer, a physician-scientist and professor at Rutgers New Jersey Medical School, emphasized the importance of study design when addressing these conditions. "How can studies produce concrete conclusions about Lyme when you don't know if patients really had Lyme disease or if they had a mimicking condition?" he asked.
The researchers point out that many studies include participants with only Lyme antibodies or bull's-eye rashes rather than documenting Borrelia burgdorferi, the bacterium responsible for Lyme disease. Lone Star tick bites and other conditions can produce identical rashes, making it difficult to determine if patients truly have Lyme disease.
"This recurring problem of unproven diagnoses undermines the credibility of studies on infection-associated chronic illnesses," Schutzer explained. "We need rigorous study design to ensure that we are accurately identifying and studying these conditions."
The article also highlights parallels with long COVID research, where similar challenges exist due to difficulties in distinguishing between different underlying mechanisms.
Jacqueline Becker, a neuropsychologist at the Icahn School of Medicine at Mount Sinai, "patients with post-infectious conditions have been waiting far too long for answers." She emphasized the need for clinical trials that confirm diagnoses and treat patient populations as distinct rather than lumping everyone together.
Avindra Nath, physician-scientist and clinical director of the NIH's National Institute of Neurological Disorders and Stroke, added, "The framework we advocate is a major step forward since it provides rigorous and well-thought-out guidelines for every aspect of conducting clinical trials in this patient population."
While progress has been made with treatments like multiple sclerosis medications that have FDA approval based on rigorous study design, the authors believe that similar approaches are needed to develop effective therapies for post-infectious conditions.
"This is a critical issue," Becker concluded. "We must get the fundamentals right if we want clinical trials that actually lead to treatments."
The findings underscore the importance of methodological rigor in studies of infection-triggered chronic illnesses and highlight the need for more precise diagnosis and treatment approaches.
